{"id":9921,"date":"2021-08-10T09:20:24","date_gmt":"2021-08-10T07:20:24","guid":{"rendered":"https:\/\/ggba.swiss\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/"},"modified":"2023-07-04T13:43:40","modified_gmt":"2023-07-04T11:43:40","slug":"obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/","title":{"rendered":"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions"},"content":{"rendered":"<p><a href=\"https:\/\/www.obseva.com\/\" target=\"_blank\" rel=\"noopener\">ObsEva<\/a> est une soci\u00e9t\u00e9 biopharmaceutique qui d\u00e9veloppe et commercialise de nouvelles th\u00e9rapies pour am\u00e9liorer la sant\u00e9 reproductive des femmes et la grossesse.<\/p>\n<p>Gr\u00e2ce \u00e0 l&rsquo;acquisition de licences strat\u00e9giques et au d\u00e9veloppement syst\u00e9matique de nouveaux m\u00e9dicaments, ObsEva a \u00e9tabli un pipeline clinique de stade avanc\u00e9 avec des programmes de d\u00e9veloppement ax\u00e9s sur de nouvelles th\u00e9rapies pour le traitement des fibromes ut\u00e9rins, de l&rsquo;endom\u00e9triose et du travail pr\u00e9-terme.<\/p>\n<p>Le m\u00e9dicament candidat de la soci\u00e9t\u00e9, l&rsquo;<a href=\"https:\/\/www.obseva.com\/obe022\/\" target=\"_blank\" rel=\"noopener\">ebopiprant<\/a>, est un antagoniste s\u00e9lectif et exp\u00e9rimental des r\u00e9cepteurs de la prostaglandine, administr\u00e9 par voie orale, et \u00e9valu\u00e9 comme traitement potentiel du travail pr\u00e9-terme en r\u00e9duisant l&rsquo;inflammation et les contractions ut\u00e9rines.<\/p>\n<p>S&rsquo;il est approuv\u00e9, l&rsquo;ebopiprant a le potentiel de devenir une innovation de choix pour cette maladie courante et grave, pour laquelle il n&rsquo;existe aucun traitement approuv\u00e9 pour le traitement aigu du travail pr\u00e9-terme aux \u00c9tats-Unis.<\/p>\n<p>En concluant un accord avec <a href=\"https:\/\/www.organon.com\/\" target=\"_blank\" rel=\"noopener\">Organon<\/a>, une entreprise internationale sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, ObsEva obtiendra les droits mondiaux de d\u00e9veloppement, de fabrication et de commercialisation de l&rsquo;ebopiprant. L&rsquo;entreprise bas\u00e9e \u00e0 Gen\u00e8ve recevra jusqu&rsquo;\u00e0 USD 500 millions, dont USD 25 millions en paiement initial.<\/p>\n<p>Organon a l&rsquo;intention de travailler avec les communaut\u00e9s scientifiques et m\u00e9dicales et les autorit\u00e9s r\u00e9glementaires des principaux march\u00e9s, y compris les \u00c9tats-Unis, pour faire avancer le d\u00e9veloppement clinique et l&rsquo;enregistrement de l&rsquo;ebopiprant.<\/p>\n<p>Brian O&rsquo;Callaghan, CEO d&rsquo;ObsEva, a comment\u00e9 : \u00ab\u00a0Organon est le partenaire id\u00e9al pour le d\u00e9veloppement et la commercialisation de l&rsquo;ebopiprant et nous consid\u00e9rons cet accord comme une \u00e9tape importante dans l&rsquo;avancement de cet agent exp\u00e9rimental. Bien que les taux de naissances pr\u00e9matur\u00e9es soient en hausse, il n&rsquo;y a actuellement aucun autre compos\u00e9 connu en d\u00e9veloppement. C&rsquo;est pourquoi nous nous concentrons sur l&rsquo;\u00e9valuation de cet agent dans un domaine important de besoins non satisfaits. Avec les donn\u00e9es g\u00e9n\u00e9r\u00e9es \u00e0 ce jour, cet accord souligne la valeur de notre produit et nous sommes impatients de concr\u00e9tiser notre vision commune.\u00a0\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ObsEva, une soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e \u00e0 Gen\u00e8ve qui se consacre \u00e0 l&rsquo;am\u00e9lioration de la sant\u00e9 reproductive des femmes, recevra jusqu&rsquo;\u00e0 USD 500 millions pour l&rsquo;octroi de licences pour son m\u00e9dicament candidat, l\u2019ebopiprant.<\/p>\n","protected":false},"author":3,"featured_media":9922,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1022,1068,1069],"class_list":["post-9921","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr","tag-personalized-medicine-fr","tag-pharma-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"ObsEva, une soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e \u00e0 Gen\u00e8ve qui se consacre \u00e0 l&#039;am\u00e9lioration de la sant\u00e9 reproductive des femmes, recevra jusqu&#039;\u00e0 USD 500 millions pour l&#039;octroi de licences pour son m\u00e9dicament candidat, l\u2019ebopiprant.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-10T07:20:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:43:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions\",\"datePublished\":\"2021-08-10T07:20:24+00:00\",\"dateModified\":\"2023-07-04T11:43:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/\"},\"wordCount\":388,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg\",\"keywords\":[\"Biotech\",\"Personalized Medicine\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/\",\"name\":\"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg\",\"datePublished\":\"2021-08-10T07:20:24+00:00\",\"dateModified\":\"2023-07-04T11:43:40+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions - Greater Geneva Bern area","og_description":"ObsEva, une soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e \u00e0 Gen\u00e8ve qui se consacre \u00e0 l'am\u00e9lioration de la sant\u00e9 reproductive des femmes, recevra jusqu'\u00e0 USD 500 millions pour l'octroi de licences pour son m\u00e9dicament candidat, l\u2019ebopiprant.","og_url":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2021-08-10T07:20:24+00:00","article_modified_time":"2023-07-04T11:43:40+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions","datePublished":"2021-08-10T07:20:24+00:00","dateModified":"2023-07-04T11:43:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/"},"wordCount":388,"image":{"@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg","keywords":["Biotech","Personalized Medicine","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/","url":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/","name":"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg","datePublished":"2021-08-10T07:20:24+00:00","dateModified":"2023-07-04T11:43:40+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-3.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/obseva-societe-biopharmaceutique-specialisee-sante-femmes-recoit-usd-500-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"ObsEva, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la sant\u00e9 des femmes, re\u00e7oit USD 500 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=9921"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9921\/revisions"}],"predecessor-version":[{"id":17966,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9921\/revisions\/17966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/9922"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=9921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=9921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=9921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}